Matthew Bogyo Selected Research

Therapeutics

1/2019	Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
6/2017	Toxoplasma depends on lysosomal consumption of autophagosomes for persistent infection.
1/2017	Protein Degradation Systems as Antimalarial Therapeutic Targets.
11/2016	Design of Selective Substrates and Activity-Based Probes for Hydrolase Important for Pathogenesis 1 (HIP1) from Mycobacterium tuberculosis.
1/2016	A Bright Future for Precision Medicine: Advances in Fluorescent Chemical Probe Design and Their Clinical Application.
10/2012	Active cathepsins B, L, and S in murine and human pancreatitis.
4/2012	Treatment of arthritis by macrophage depletion and immunomodulation: testing an apoptosis-mediated therapy in a humanized death receptor mouse model.
8/2008	Trial of the cysteine cathepsin inhibitor JPM-OEt on early and advanced mammary cancer stages in the MMTV-PyMT-transgenic mouse model.
8/2007	Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew Bogyo Research Topics

Disease

48	Neoplasms (Cancer) 05/2024 - 05/2004
19	Malaria 01/2023 - 12/2002
13	Infections 10/2022 - 02/2007
12	Inflammation (Inflammations) 01/2020 - 11/2011
10	Carcinogenesis 12/2017 - 05/2004
9	Neoplasm Metastasis (Metastasis) 12/2019 - 05/2006
7	Breast Neoplasms (Breast Cancer) 05/2023 - 05/2006
4	Carcinoma (Carcinomatosis) 01/2020 - 05/2004
4	Atherosclerosis 10/2016 - 02/2012
3	Skin Neoplasms (Skin Cancer) 01/2020 - 02/2017
3	Parasitic Diseases (Parasitic Disease) 01/2019 - 07/2004
3	Pathologic Processes 01/2018 - 01/2007
3	Disease Progression 10/2016 - 10/2012
3	Pain (Aches) 01/2016 - 11/2011
3	Rupture 05/2011 - 11/2006
2	Virus Diseases (Viral Diseases) 10/2022 - 12/2019
2	Colitis 01/2020 - 11/2011
2	Falciparum Malaria (Plasmodium falciparum Malaria) 01/2019 - 01/2017
2	Colonic Neoplasms (Colon Cancer) 01/2018 - 12/2016
2	Hematologic Neoplasms (Hematological Malignancy) 11/2017 - 01/2017
2	Clostridium Infections 12/2016 - 09/2015
2	Pancreatic Neoplasms (Pancreatic Cancer) 10/2016 - 01/2016
2	Pancreatitis 01/2016 - 10/2012
2	Chronic Pancreatitis 01/2016 - 10/2012
2	Atherosclerotic Plaque (Atheroma) 01/2016 - 08/2004
2	Neuroblastoma 05/2015 - 05/2009
2	Hyperplasia 12/2012 - 04/2012
2	Thyroid Neoplasms (Thyroid Cancer) 08/2011 - 08/2010
1	Glioma (Gliomas) 03/2024
1	Glioblastoma (Glioblastoma Multiforme) 03/2024
1	Type 2 Diabetes Mellitus (MODY) 12/2023
1	Tuberculosis (Tuberculoses) 01/2022
1	COVID-19 11/2021
1	Residual Neoplasm 09/2020
1	Frontotemporal Dementia (Semantic Dementia) 01/2020
1	Dysbiosis 01/2020
1	Toxoplasmosis 01/2019
1	Paralysis (Palsy) 01/2019
1	Mucolipidoses (Sialidosis) 01/2018
1	Brain Neoplasms (Brain Tumor) 12/2017

Drug/Important Bio-Agent (IBA)

41	Peptide Hydrolases (Proteases)FDA Link 05/2024 - 12/2002
39	CathepsinsIBA 03/2024 - 05/2004
19	Cysteine (L-Cysteine)FDA Link 03/2024 - 05/2004
14	Cysteine Proteases (Cysteine Protease)IBA 01/2019 - 12/2002
13	Proteins (Proteins, Gene)FDA Link 12/2019 - 05/2004
11	EnzymesIBA 10/2022 - 06/2006
8	Cathepsin BIBA 12/2017 - 09/2005
7	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2023 - 08/2014
6	Contrast MediaIBA 05/2024 - 01/2011
6	PapainIBA 11/2021 - 05/2007
6	Biomarkers (Surrogate Marker)IBA 01/2018 - 01/2011
5	Antimalarials (Antimalarial Agents)IBA 12/2018 - 08/2010
4	AminopeptidasesIBA 01/2019 - 01/2011
4	asparaginylendopeptidase (legumain)IBA 01/2016 - 02/2010
3	Fluorescent Dyes (Fluorescent Probes)IBA 05/2024 - 01/2020
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2022 - 09/2015
3	Indicators and Reagents (Reagents)IBA 11/2016 - 10/2013
3	Cathepsin LIBA 10/2014 - 07/2004
3	Hemoglobins (Hemoglobin)IBA 11/2013 - 11/2006
2	artemisinin (artemisinine)IBA 01/2023 - 01/2017
2	HydrolasesIBA 10/2021 - 10/2016
2	ebselenIBA 01/2020 - 12/2016
2	ProgranulinsIBA 01/2020 - 01/2017
2	Metalloproteases (Metalloproteinases)IBA 01/2019 - 01/2018
2	Molecular Probes (Molecular Probe)IBA 01/2019 - 12/2016
2	Protease Inhibitors (Protease Inhibitor)IBA 12/2017 - 08/2011
2	Proteasome InhibitorsIBA 11/2017 - 02/2016
2	cathepsin SIBA 10/2016 - 11/2011
2	ElastinIBA 10/2016 - 08/2004
2	InflammasomesIBA 03/2016 - 09/2012
2	CeruletideIBA 01/2016 - 10/2012
2	Peptides (Polypeptides)IBA 10/2014 - 05/2007
2	CollagenIBA 10/2013 - 08/2008
2	JPM 565IBA 08/2008 - 08/2007
2	Cysteine Proteinase InhibitorsIBA 03/2008 - 02/2007
2	AntigensIBA 03/2008 - 05/2007
2	falcipainIBA 06/2006 - 12/2002
1	PolymersIBA 05/2024
1	Caspase 3 (Caspase-3)IBA 03/2024
1	SuspensionsIBA 03/2024
1	Proline (L-Proline)FDA Link 12/2023
1	HydrogelsIBA 07/2022
1	LipidsIBA 10/2021
1	Amino Acids FDA Link 10/2020
1	GranulinsIBA 01/2020
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2019
1	DipeptidesIBA 01/2019
1	ZincIBA 01/2018
1	CarbohydratesIBA 01/2018
1	EndopeptidasesIBA 01/2018
1	Matrix Metalloproteinases (MMPs)IBA 01/2018
1	TubulinIBA 12/2017

Therapy/Procedure

9	Therapeutics 01/2019 - 08/2007
2	Computer-Assisted Surgery (Image Guided Surgery) 05/2024 - 09/2020
2	Mohs Surgery (Mohs' Micrographic Surgery) 01/2020 - 02/2017
2	Endoscopes 01/2018 - 12/2016
2	Drug Therapy (Chemotherapy) 05/2015 - 08/2007
1	Radiotherapy 07/2022
1	Segmental Mastectomy (Lumpectomy) 09/2020
1	Lasers (Laser) 01/2018